Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB705498 · 2 trials · 2 indications
Pain intensity was assessed using VAS. These assessments were then summarized to give a weighted mean score. The VAS was a subjective assessment of post-operative pain intensity. The participants rated the pain intensity at the time of assessment by marking a line on a 100 millimeter (mm) (0 to 100 mm) long scale. A line placed on the extreme left (0 mm) indicated no pain and extreme right (100 mm) indicated worst pain imaginable. This scale has no subscales. Only those participants available at the specified time points were analyzed.
| Arm | Type | Description |
|---|---|---|
| Placebo | EXPERIMENTAL | Eligible participants received a single dose of SB705498 matching placebo capsules (4 placebo capsules) via oral route and were followed up to a maximum of 14 days. |
| SB705498 400 mg | EXPERIMENTAL | Eligible participants received a single dose of SB705498 400 milligram (mg) capsules (2 x 200 mg capsules plus 2 placebo capsules) via oral route and were followed up to a maximum of 14 days. |
| SB705498 1000 mg | EXPERIMENTAL | Eligible participants received a single dose of SB705498 1000 mg capsules (2 x 200 mg capsules plus 2 x 300 mg capsules) via oral route and were followed up to a maximum of 14 days. |
| Co-Codamol | EXPERIMENTAL | Eligible participants received a single dose of Co-codamol capsules (2 x Paracetamol Ph Eur 500 mg, codeine phosphate hemihydrate Ph Eur 12.8 mg plus two placebo capsules) via oral route and were followed up to a maximum of 14 days. |
| study population | EXPERIMENTAL | All subjects will receive 1%, 3%, 5% (w/w) of SB705498 and a placebo comparator |
| Name | Type | Description |
|---|---|---|
| SB705498 400 mg | DRUG | SB705498 400 mg |
| SB705498 1000 mg | DRUG | SB705498 1000 mg |
| Placebo | DRUG | Placebo |
| Co-Codamol | DRUG | Co-Codamol |
| SB705498 | DRUG | 1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study. |
Inclusion criteria: * Female or male subjects aged 18 to 50. Women may be of child bearing potential or of non-child bearing potential. Women of child bearing potential must use an effective method of contraception (see below). * Females of non-child bearing potential are defined as: * Post-menopau...
SB-705498 is an investigational small molecule being studied for atopic dermatitis, toothache, acute migraine, and rhinitis. It has been evaluated in clinical trials for acute migraine treatment and for rhinitis, including allergic rhinitis. The drug is in Phase 2 development and remains investigational, not approved.
SB-705498 is a small molecule developed by GSK plc. It has been studied in neurology and other therapeutic areas for conditions including migraine and rhinitis. The specific molecular target of SB-705498 is not disclosed in the available clinical trial information.
SB-705498 is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The drug is an investigational small molecule in Phase 2 clinical development for multiple indications.
SB-705498 is in Phase 2 clinical development. It has completed six clinical trials, including Phase 1 and Phase 2 studies, with no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities.
SB-705498 has completed six clinical trials, including NCT00269022 for acute migraine, NCT00731250 and NCT00907933 for rhinitis in healthy volunteers, and NCT01424397 for allergic rhinitis. All trials are completed with no active studies currently enrolling.
SB-705498 is the primary name used in clinical trials and development records. No alternative names have been reported in the available clinical trial information. The drug is identified solely as SB-705498 across all completed studies.